By Fineline Cube Innovative Medical Management Co., Ltd. (SHE: 002173) announced that its holding subsidiary Cereblink (Hangzhou) Technology Co., Ltd. has obtained a medical device registration certificate for the “Active-Passive Upper Limb Rehabilitation Training System” (Cereblink AM5). The system is indicated for rehabilitation training in patients with upper limb dysfunction caused by central nervous system injury.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Medical device registration certificate |
| Product | Cereblink AM5 Active-Passive Upper Limb Rehabilitation Training System |
| Indication | Rehabilitation training for upper limb dysfunction due to central nervous system injury |
| Approval Date | 30 Jun 2026 |
| Developer | Cereblink (Hangzhou) Technology Co., Ltd. (wholly-owned subsidiary of Innovative Medical Management) |
Technology Profile & Innovation
- Platform: Upper limb exoskeleton rehabilitation training system
- Core Technology: Real-time surface electromyographic (EMG) signal capture and processing
- Innovation: Proprietary algorithm recognizes patient movement intentions from muscle signals, enabling the exoskeleton to provide synchronized assistance
- Training Modes: Active-passive hybrid approach adapts to patient’s residual motor function
The Cereblink AM5 represents a significant advancement in neurorehabilitation technology by bridging the gap between patient intention and mechanical assistance. Unlike conventional passive rehabilitation devices that operate on pre-programmed movements, the AM5 system detects subtle muscle activation patterns through surface EMG sensors, interprets the patient’s intended movement direction and intensity, and then drives the exoskeleton to complete the motion with appropriate assistance levels.
This intention-driven approach promotes neuroplasticity and motor relearning by ensuring that every movement initiated by the patient—regardless of how weak—is successfully completed with robotic support, creating a positive feedback loop essential for central nervous system recovery.
Commercial Positioning
| Milestone | Strategic Impact |
|---|---|
| Subsidiary Structure | Cereblink operates as specialized medtech innovation arm within Innovative Medical Management portfolio |
| Market Focus | Addresses growing demand for advanced neurorehabilitation solutions in China’s aging population |
| Technology Differentiation | EMG-driven intention recognition sets AM5 apart from competing passive exoskeleton systems |
| Regulatory Pathway | Medical device registration enables immediate commercial deployment in Chinese rehabilitation centers |
China faces increasing demand for advanced rehabilitation technologies, with an estimated 2.5 million new stroke cases annually and millions more living with permanent motor disabilities. The Cereblink AM5 targets this substantial unmet need with a solution that combines cutting-edge EMG signal processing with practical clinical application.
Market Impact & Outlook
- Rehabilitation Market: China’s rehabilitation medical device market is projected to reach ¥30 billion ($4.2 billion) by 2028, growing at 15% CAGR
- Clinical Advantage: Intention-driven therapy may accelerate recovery timelines and improve functional outcomes compared to traditional passive modalities
- Commercial Strategy: Innovative Medical Management leverages its healthcare network to facilitate rapid adoption across rehabilitation hospitals and clinics
- Competitive Landscape: The AM5 competes with both domestic passive exoskeletons and imported active systems, offering a unique middle ground with EMG-driven assistance
Forward-Looking Statements
This brief contains forward-looking statements regarding market opportunities and commercial expectations for the Cereblink AM5 system. Actual results may differ due to risks including market adoption rates, competitive dynamics, and healthcare reimbursement policies.-Fineline Info & Tech